Moclobemide: Therapeutic use and clinical studies

CNS Drug Reviews

Volumn 9, Issue 1, 2003, Pages 97-140

  Bonnet, Udo ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Antidepressants; MAO Inhibitors; Moclobemide

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DEXTROPROPOXYPHENE; DOSULEPIN; DOXEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; OPIATE; PETHIDINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; TYRAMINE;

AGITATED DEPRESSION; ANTICHOLINERGIC EFFECT; ANTICONVULSANT ACTIVITY; ANXIETY DISORDER; ATYPICAL DEPRESSION; BIPOLAR DEPRESSION; BRAIN INJURY; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; COGNITION; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMENTIA; DEPRESSION; DISCONTINUATION SYNDROME; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MIXTURE; DRUG OVERDOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSTHYMIA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSIVE CRISIS; INSOMNIA; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MANIA; META ANALYSIS; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NAUSEA; ORGANIC DEPRESSION; PANIC; PATIENT MONITORING; POSTSTROKE DEPRESSION; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; REACTIVE DEPRESSION; REFRACTORY DEPRESSION; RETARDED DEPRESSION; REVIEW; SEIZURE; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SOCIAL PHOBIA; STEADY STATE; VERTIGO; WEIGHT GAIN;

EID: 0037361293     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2003.tb00245.x     Document Type: Review

References (265)

1. Alderman CP, Callary JA, Kent AL. Peripheral oedema associated with moclobemide. Med J Aust 1992;157:144.
2. Allain H, Lieury A, Brunet-Bourgin F, et al. Antidepressants and cognition: Comparative effects of moclobemide, viloxazine and maprotiline. Psychopharmacology 1992;106:S56-S61.
3. Altamura AC, Aguglia E. Moclobemide vs. fluoxetine in elderly outpatients with major depression or dysthymia: A double-blind trial. Eur Psychiatry 1994;9(Suppl 1):163S.
4. Amrein R, Allen SR, Vranesic D, et al. Antidepressant drug therapy: Associated risks. J Neural Transm 1988;26(Suppl):73-86.
5. Amrein R, Güntert TW, Dingemanse J, et al. Interactions of moclobemide with concomitantly administered medication: evidence from pharmacological and clinical studies. Psychopharmacology 1992;106:S24-S31.
6. Amrein R, Stabl M, Henauer S, et al. Efficacy and tolerability of moclobemide in comparison with placebo, tricyclic antidepressants, and selective serotonin reuptake inhibitors in elderly depressed patients: A clinical overview. Can J Psychiatry 1997;42:1043-1050.
7. Amrein R, Martin JR, Cameron AM. Moclobemide in patients with dementia and depression. Adv Neurol 1999;80:509-519.
8. Anand R, Wesnes KA. Cognition-enhancing effects of moclobemide, a reversible MAO inhibitor, in humans. Adv Neurol 1990;51:261-268.
9. Angst J, Stabl M. Efficacy of moclobemide in different patient groups: A meta-analysis of studies. Psychopharmacology 1992;106(Suppl):S109-S113.
10. Angst J, Scheidegger P, Stabl M. Efficacy of moclobemide in different patient groups - results of new subscales of the Hamilton Depression Scale. Clin Neuropharmacol 1993;16(Suppl 2):S55-S62.
11. Angst J, Johnson FN. Moclobemide in special sub-groups of depression. Rev Contemp Psychopharmacother 1994;5:45-55.
12. Angst J, Amrein R, Stabl M. Moclobemide and tricyclic antidepressants in severe depression: Meta-analysis and prospective studies. J Clin Psychopharmacol 1995;15(Suppl 2):16S-23S.
13. Ballenger JC, Wheadon DE, Steiner M, et al. Double-blind-fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1988;155:36-42.
14. Bakish D, Bradweijn J, Nair N, et al. A comparison of moclobemide, amitriptyline and placebo in depression: A Canadian multicentre study. Psychopharmacology 1992;106:S98-S101.
15. Bakish D, Hooper CL, West DL, et al. Moclobemide and specific serotonin re-uptake inhibitor combination treatment of resistant anxiety and depressive disorders. Hum Psychopharmacol 1995;10:105-109.
16. Barak Y, Suholitsky H, Noy S. Moclobemide treatment of resistant depression in a patient with vascular dementia. Hum Psychopharmacol 1996;11:67-68.
17. Barak Y, Ur E, Achiron A. Moclobemide treatment in multiple sclerosis patients with comorbid depression: An open-label safety trial. J Neuropsych Clin Neurosci 1999;11:271-273.
18. Barlow DH. Cognitive-behavioral therapy in panic disorder: Current status. J Clin Psychiatry 1997;58(Suppl 2):32-36.
19. Barrelet L, Blajev B, Bolzani L, et al. Multicenter study comparing efficacy and tolerability of moclobemide and fluvoxamine in in- and outpatients with a severe depressive episode. Schweiz Rundsch Med Prax 1991;80:524-528.
20. Baumbacher G, Hansen MS. Abuse of monoamine oxidase inhibitors. Am J Drug Alcohol Abuse 1992;18:399-406.
21. Baumann P, Eap CB, Koeb L, et al. Pharmacogenetic investigations in moclobemide (MOCL) plus thioridazine (THD) vs. MOCL plus placebo-treated depressive patients. Neuropsychopharmacology 1994;10:75S.
22. Baumhackl U, Biziere K, Fischbach R, et al. Efficacy and tolerability of moclobemide compared with imipramine in depressive disorder (DSM-III): An Austrian double-blind, multicentre study. Br J Psychiatry 1989;6:78-83.
23. Beasley C, Mascia DN, Heiligenstein JH, et al. Possible monoamine oxidase inhibitor - serotonin uptake inhibitor interaction: Fluoxetine clinical data and preclinical findings. J Clin Psychopharmacol 1993;13:312-320.
24. Beaumont G, Gringas M, Hobbs FD, et al. A randomized, double-blind, multi-centre, parallel-group study comparing the tolerability and efficacy of moclobemide and dothiepin hydrochloride in depressed patients in general practice. Int Clin Psychopharmacol 1993;7:159-165.
25. Benazzi F. Serotonin syndrome with moclobemide-fluoxetine combination. Pharmacopsychiatry 1996;29:162.
26. Berlin I, Cournot A, Zimmer R, et al. Evaluation and comparison of the interaction between alcohol and moclobemide or clomipramine in healthy subjects. Psychopharmacology 1990;100:40-45.
27. Berlin I, Said S, Spreux-Varoquaux O, et al. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin Pharmacol Ther 1995;58:444-452.
28. Bisserbe J-C, Lépine J-P and the GRP group. Moclobemide in social phobia: A pilot open study. Clin Neuropharmacol 1994;17(Suppl 1):S88-S94.
29. Blackwell B. Monoamine oxidase inhibitor interactions with other drugs. J Clin Psychopharmacol 1991;11:55-59.
30. Blier P, Bergeron R. The safety of concomitant use of sumatriptan and antidepressant treatments. J Clin Psychopharmacol 1995;15:106-109.
31. Bocksberger JP, Gachoud JP, Richard J, et al. Comparison of the efficacy of moclobemide and fluvoxamine in elderly patients with a severe depressive episode. Eur Psychiatry 1993;8:319-324.
32. Bonnet U, Leniger T, Wiemann M. Moclobemide reduces intracellular pH and neuronal activity of CA3 neurones in guinea-pig hippocampal slices - implication for its neuroprotective properties. Neuropharmacology 2000;39:2067-2074.
33. Bonnet U. Moclobemide: Evolution, Pharmacodynamic and Pharmacokinetic Properties. CNS Drug Rev 2002;8:283-308.
34. Botte L, Gilles C, Evrard JL. Moclobemide vs. placebo in the treatment of depression: A multicentre study in Belgium. Acta Psychiatr Scand 1990;82(Suppl 360):42.
35. Botte L, Everard L, Gillies C, et al. Controlled comparison of Ro 11-1163 (moclobemide) and placebo in the treatment of depression. Acta Psychiatr Belg 1992;92:355-369.
36. Bougerol T, Uchida C, Gachoud J-P, et al. Efficacy and tolerability of moclobemide compared with fluvoxamine in depressive disorder (DSM III). A French/Swiss double-blind trial. Psychopharmacology 1992;106(Suppl):102-108.
37. Bugarski-Kirola D, Zivkovic D, Stankovic Z. Fluoxetine vs. moclobemide in elderly depressed patients. Eur Neuropsychopharmacol 1996;6(Suppl 1):20.
38. Burner M. Moclobemid vs. Maprotilin. Multizenter Studie mit ambulant behandelten Patienten mit typischer depressiver Episode nach DSM-111. Der informierte Arzt - Gazette Medicale, Schweiz Z Therap Fortbild 1990;14:1371-1375.
39. Camaris C, Little D. A fatality due to moclobemide. J Forensic Sci 1997;42:945-955.
40. Carruba MO, Cuzzolaro M, Riva L, et al. Efficacy and tolerabilty of moclobemide in bulimia nervosa: A placebo-controlled trial. Int Clin Psychopharmacol 2001;16:27-32.
41. Casacchia M, Carolei A, Barba C, et al. A placebo-controlled study of the antidepressant activity of moclobemide: A new MAO-inhibitor. Pharmacopsychiatry 1984;17:122-125.
42. Casacchia M, Rossi A. A comparison of moclobemide and imipramine in the treatment of depression. Pharmacopsychiatry 1989;22:152-155.
43. Chan-Palay V. Depression and senile dementia of the Alzheimer type: A role for moclobemide. Psychopharmacology 1992;106:S137-S139.
44. Chaudry HR. Clinical use of moclobemide in Kleine-Levin syndrome. Br J Psychiatry 1992;161:720.
45. Chen DT, Ruch R. Safety of moclobemide in clinical use. Clin Neuropharmacol 1993;16(Suppl 2):63-68.
46. Civeira J, Cervera S, Giner J, et al. Moclobemide vs. clomipramine in the treatment of depression: A multicenter trial in Spain. Acta Psychiatr Scand 1990;82(Suppl 360):48-49.
47. Claman JM. The potential effectiveness of moclobemide, the new monoamine oxidase inhibitor, in the prophylaxis of migraine. Headache 1993;33:339.
48. Coulter DM, Phillans Pl. Hypertension with moclobemide. Lancet 1996;347:1032-1033.
49. Coupland NJ, Wilson SJ, Potokar JP, et al. A comparison of the effects of phenelzine treatment with moclobemide treatment on cardiovascular reflexes. Int Clin Psychopharmacol 1995;10:229-238.
50. Curran S, de Pauw K. Selecting an antidepressant for use in a patient with epilepsy. Safety considerations. Drug Safety 1998;18:125-133.
51. Danish University Antidepressant Group. Moclobemide: A reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1993;28:105-118.
52. Dams R, Benijts THP, Lambert WE, et al. A fatal case of serotonin syndrome after combined moclobemidecitalopram intoxication. J Anal Toxicol 2001;25:147-151.
53. Da Prada, M, Zürcher G, Wüthrich I, et al. On tyramine, food, beverages, and reversible MAO inhibitor moclobemide. J Neural Transm 1988;26(Suppl):31-36.
54. Da Prada M, Zürcher G. Tyramine content of preserved and fermented foods or condiments of Far Eastern cuisine. Psychopharmacology 1992;106:S32-S34.
55. Davies JM, Wang Z, Janicak PG. A quantitative analysis of clinical drug trials for the treatment of affective disorders. Psychopharmacol Bull 1993;29:175-181.
56. Davis D, Ralevski E, Kennedy SH, et al. The role of personality factors in the reporting of side effect complaints to moclobemide and placebo: A study of healthy male and female volunteers. J Clin Psychopharmacol 1995;15:347-352.
57. Delini-Stula A, Mikkelsen H. Risk of 5-HT syndrome after co-adminstration of moclobemide (RIMA) and selective 5-HT re-uptake inhibitors (SSRI) - analyses of cases. Eur Neuropsychopharmacol 1993;3:337-338.
58. Delini-Stula A, Mikkelsen H, Angst J. Therapeutic efficacy of antidepressants in agitated anxious depression - a meta-analysis of moclobemide studies. J Affect Disord 1995;35:21-30.
59. Delini-Stula A, Baier D, Kohen R, et al. Undesirable blood pressure changes under naturalistic treatment with moclobemide, a reversible MAO-A inhibitor - results of the drug utilization observation studies. Pharmacopsychiatry 1999;32:61-67.
60. de Jonghe F, Kool S, van Aalst G, et al. Combining psychotherapy and antidepressants in the treatment of depression. J Affect Disord 2001;64:217-229.
61. de Mello MF, Myczcowisk LM, Menezes PR. A randomized controlled trial comparing moclobemide and moclobemide plus interpersonal psychotherapy in the treatment of dysthymic disorder. J Psychother Pract Res 2001;10:117-123.
62. De Vanna M, Kummer J, Agnoli A, et al. Moclobemide compared with second-generation antidepressants in elderly people. Acta Psychiatr Scand 1990;82(Suppl 360):64-66.
63. Dierick M, Cattiez P, Burton P, et al. Moclobemide vs. clomipramine in the treatment of depression: A double-blind multicenter study in Belgium. Acta Psychiatr Scand 1990;82(Suppl 360):50-51.
64. Dingemanse J, Korn A, Pfefen J-P, et al. Biochemical effects of high single doses of moclobemide in man: Correlation with plasma concentrations. Psychopharmacology 1992;106:S46-S48.
65. Dingemanse J. An update of recent moclobemide interaction data. Int Clin Psychopharmacol 1993;7:167-179.
66. Dingemanse J, Kneer J, Fotteler B, et al. Switch treatments from tricyclic antidepressants to moclobemide: A new generation oxidase inhibitor. J Clin Psychopharmacol 1995;15:41-48.
67. Dingemanse J, Kneer J, Wallnöfer A, et al. Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors: Moclobemide and selegiline. Clin Neuropharmacol 1996;19:399-414.
68. Dingemanse J, Wood N, Guentert T, et al. Clinical pharmacology of moclobemide during chronic administration of high doses to healthy subjects. Psychopharmacology 1998;140:164-172.
69. Dingemanse J, Wallnöfer A, Gieschke R, et al. Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigation of the "serotonin syndrome." Clin Pharmacol Ther 1998;63:403-413.
70. Dixon CM, Park GR, Tarbit MH. Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver. Biochem Pharmacol 1994;47:1253-1257.
71. Dollow S. Antidepressant-associated fatal intrahepatic cholestasis. Lancet 1996;347:1268.
72. Dönbak SO, Turkcapar MH, Kilic EZO, et al. Moclobemide and sertraline in the treatment of depressive disorders: A comparative study. Acta Psychiatr Belg 1995;95:139-151.
73. Duarte A, Mikkelsen H, Delini-Stula A. Moclobemide vs. fluoxetine for double depression: A randomized double-blind study. J Psychiatr Res 1996;30:453-458.
74. Duncan D, Sayal K, McConnell H, et al. Antidepressant interactions with warfarin. Int Clin Psychopharmacol 1998;13:87-94.
75. Eadie MJ. Clinically significant drug interactions with agents specific for migraine attacks. CNS Drugs 2001;15:105-118.
76. Ebert D, Demling J. Successful tratment of tardive akathisia with moclobemide, a reversible and selective monoamine-oxidase-A inhibitor. A case study. Pharmacopsychiatry 1991;24:229-231.
77. Ebert D, Albert R, May J, et al. Combined SSRI-RIMA therapy in refractory depression - safety data and efficacy. Psychopharmacology 1995;119:324-344.
78. Evans L, George T, O'Sullivan B, et al. An Australian multicenter study of moclobemide vs. amitryptiline in the treatment of depression. Aust NZ J Psychiatry 1992;26:454-458.
79. Fairweather DB, Hindmarch I. The behavioural toxicity of reversible inhibitors of monoamine oxidase A: laboratory and clinical investigations. J Clin Psychopharmacol 1995;15(Suppl 2):68S-75S.
80. Fava M. Management of nonresponse and intolerance: switching strategies. J Clin Psychiatry 2000;61(Suppl 2):10-12.
81. Fawcett J, Barkin RL. Efficacy issues with antidepressants. J Clin Psychiatry 1997;58(Suppl 6):32-39
82. Ferrer-Dufol A, Perez-Arados C, Murillo EC, Marques-Alamo JM. Fatal serotonin syndrome caused by moclobemide-clomipramine oversdose. Clin Toxicol 1998;36:31-32.
83. Fischer P. Serotonin syndrome in the elderly after antidepressive monotherapy. J Clin Psychopharmacol 1995;15:440-442.
84. Fitton A, Faulds D, Goa KL. Moclobemide - a review of its pharmacological properties and therapeutic use in depressive illness. Drugs 1992;43:561-596.
85. Fleishaker JC, Ryan KK, Jansat JM, et al. Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. Br J Clin Pharmacol 2001;51:437-441.
86. Fulton B, Benfield P. Moclobemide - an update of its pharmacological properties and therapeutic use. Drugs 1996;52:450-474.
87. Funke HJ, Moritz F, Hellern K, et al. Moclobemide vs. clomipramine in the treatment of depression: A single centre study, Federal Republic of Germany. Acta Psychiatr Scand 1990;82(Suppl 360):46-47.
88. Gabelic I, Moll E. Moclobemide (Ro 11-1163) vs. desimipramine in the treatment of endogenous depression. Acta Psychiatr Scand 1990;82(Suppl 360):44-45.
89. Gachoud J-P, Dick P, Köhler M. Comparison of the efficacy and tolerability of moclobemide and maprotiline in depressed patients treated by general practioners. Clin Neuropharmacol 1994;17(Suppl 1):S29-S37.
90. Gagiano CA, Hart GAD, Bodemer W, et al. Moclobemide twice daily in the treatment of major depressive episode: A double-blind, multicenter comparison with different three-times-daily dosage schedules. Clin Neuropharmacol 1994;17(Suppl 1):S1-S8.
91. Gardner DM, Loyd LD. Sumatriptan contraindication and the serotonin syndrome. Ann Pharmacother 1998;32:33-38.
92. Gattaz WF, Vogel P, Kick H, et al. Moclobemide vs. fluoxetine in the treatment of inpatients with major depression. J Clin Psychopharmacol 1995;15(Suppl 2):35S-40S.
93. Gaudins A, Stearman A, Chan B. Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med 1998;16:615-619.
94. Gelemter CS, Uhde TW, Cimbolic P, et al. Cognitive-behavioral and pharmacological treatments of social phobia: A controlled study. Arch Gen Psychiatry 1991;48:938-945.
95. Geerts S, Bruynooghe F, De Cuyper H, et al. Moclobemide vs. fluoxetine for major depressive episodes. Clin Neuropharmacol 1994;17(Suppl 1):S50-S57.
96. Gillman PK. Possible serotonin syndrome with moclobemide and pethidine. Med J Aust 1995;162:556.
97. Goldina OA, Valdman AV. Anticonvulsant effect of some psychotropic drugs and benzamide derivates with regard to antimonoamine oxidase activity. Eur Neuropsychopharmacol 1994;4:446-447.
98. Gram LF, Guentert TW, Grange S, et al. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study. Clin Pharmacol Ther 1995;57:670-677.
99. Guelfi JD, Payan C, Fermanian J, et al. Moclobemide vs. clomipramine in endogenous depression. A double-blind randomized clinical trial. Br J Psychiatry 1992;160:519-524.
100. Güntert TW, Schmitt M, Dingemanse J, et al. Influence of moclobemide on ibuprofen-induced faecal blood loss. Psychopharmacology 1992;106:S40-S42.
101. Guentert TW, Banken L, Hilton S, et al. Moclobemide: relationships between dose, drug concentration in plasma, and occurrence of adverse events. J Clin Psychopharmacol 1995;15(Suppl 2):84S-94S.
102. Guy W. ECDEU Assessment Manual for Psychopharmacology, 12, 1976.
103. Hackett LP, Joyce DA, Hall RW, et al. Disposition and clnical effects of moclobemide and three of its metabolites following overdose. Drug Invest 1993;5:281-284.
104. Härtter S, Dingemanse J, Baier D, et al. The role of cytochrome P450 2D6 in the metabolism of moclobemide. Eur Neuropharmacol 1996;6:225-230.
105. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
106. Hannonen P, Malminiemi K, Yli-Kerttula U, et al. A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. Br J Rheumatol 1998;37:1279-1286.
107. Hawley CJ, Quick SJ, Ratnam S, et al. Safety and tolerability of combined treatment with moclobemide and SSRIs: A systematic study of 50 patients. Int Clin Psychopharmacol 1996;11:187-191.
108. Heimberg RG. Specific issues in the cognitive-behavioral treatment of social phobia. J Clin Psychiatry 1993;54(Suppl):36-45.
109. Heinze G, Rossel L, Gabelic I, et al. Double-blind comparison of moclobemide and tranylcypromine in depression. Pharmacopsychiatry 1993;26:240-245.
110. Hetzel W. Safety of moclobemide taken in overdose for attempted suicide. Psychopharmacol 1992;106:S127-S129.
111. Hilton S, Jaber B, Ruch R. Moclobemide safety: Monitoring a newly developed product in the 1990s. J Clin Psychopharmacol 1995;15(Suppl 2):76S-83S.
112. Hindmarch I, Kerr J. Behavioural toxicity of antidepressants with particular reference to moclobemide. Psychopharmacology 1992;106:S49-S55.
113. Hindmarch I, Kerr JS, Fairweather DB. The effects of moclobemide on psychomotor performance and cognitive function in the elderly. Dementia 1992;3:355-359.
114. Illi A, Sundberg S, Ojala-Karlsson P, Scheinin M, Gordin A. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers. Clin Pharmacol Ther 1996;59:450-457.
115. International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia. A double-blind, placebo controlled clinical study. Eur Arch Psychiatry Clin Neurosci 1997;24:71-80.
116. Iwersen S, Schmoldt A. Three suicide attempts with moclobemide. Clin Toxicol 1996;34:223-225.
117. Jansen Steur ENH, Ballering LAP. Combined and selective monoamine oxidase inhibition in the treatment of depression in Parkinson's disease. Adv Neurol 1999;80:505-508.
118. Joffe RT, Bakish D. Combined SSRI-moclobemide treatment of psychiatric illness. J Clin Psychiatry 1994;55:24-25.
119. Jouvent R, Le Houezec J, Payan C, et al. Dimensional assessment of onset of action of antidepressants: A comparative study of moclobemide vs. clomipramine in depressed patients with blunted affect and psychomotor retardation. Psychiatry Res 1998;79:267-275.
120. Kahn D, Silver JM, Opler LA. The safety of switching rapidly from tricyclic antidepressants to monoamine oxidase inhibitors. J Clin Psychopharmacol 1989;9:198-202.
121. Kampfhammer HP, Dieterle D, Golling H. Cimoxatone and moclobemide, two new MAO inhibitors in the treatment of major depressive disorder. Pharmacopsychiatry 1986;19:247-248.
122. Karet FE, Dickerson JE, Brown J, et al. Bovril and moclobemide: A novel therapeutic strategy for autonomic failure. Lancet 1993;344:1263-1265.
123. Kennedy SH. Continuation and maintenance treatments in major depression: The neglected role of monoamine oxidase inhibitors. J Psychiatry Neurosci 1997;22:127-131.
124. Kennedy SH, Ralevski E, Davies C, Neitzert C. The effects of moclobemide on sexual desire and function in healthy volunteers. Eur Neuropsychopharmacol 1996;6:177-181.
125. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12 month prevalence of DSM III-R psychiatric disorders in the United States. Results from a National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19.
126. Koczkas C, Holm P, Karlsson A, et al. Moclobemide and clomipramine in endogenous depression. A randomized clinical trial. Acta Psychiatr Scand 1989;79:523-529.
127. König F, Wolfersdorf M. Combination therapy using moclobemide with tricyclic and tetracyclic antidepressants to treat therapy-resistant depression. Pharmacopsychiatry 1997;30:93-96.
128. König F, Wolfersdorf M, Löble M, et al. Trimipramine and maprotiline plasma levels during combined treatment with moclobemide in therapy-resistant depression. Pharmacopsychiatry 1997;30:125-127.
129. Kok LP, Tsoi WF. A controlled double-blind trial of moclobemide and imipramine in the treatment of depression. Singapore Med J 1995;36:38-40
130. Korn A, Da Prada M, Faffesberg W, et al. Tyramine pressure effect in man: studies with moclobemide, a novel, reversible monoamine oxidase inhibitor. J Neural Transm 1988;26(Suppl):57-71.
131. Korn A, Wagner B, Moritz E, Dingemanse J. Tyramine presure sensitivity in healthy subjects during combined treatment with moclobemide and selegiline. Eur J Clin Pharmacol 1996;49:273-278.
132. Korpelainen JT, Hiltunen P, Myllylä VV. Moclobemide-induced hypersexuality in patients with stroke and Parkinson's disease. Clin Neuropharmacol 1998;21:251-254.
133. Kragh-Sorensen P, Müller B, Anddersen JV, et al. Moclobemide vs. clomipramine in depressed patients in general practice. A randomized, double blind, parallel, multicenter study. J Clin Psychopharmacol 1995;15(Suppl 2):24-30.
134. Krüger MB, Dahl AA. The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder. Eur Arch Psychiatry Clin Neurosci 1999;249(Suppl 1):S19-S24.
135. Kupfer DJ, Frank E, Perel JM, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992;49:769-773.
136. Lapierre YD, Joffe R, McKenna K, et al. Moclobemide vs. fluoxetine in the treatment of major depressive disorder in adults. J Psychiatry Neurosci 1997;22:118-126.
137. Larsen JK, Holm P, Mikkelsen PL. Moclobemide and clomipramine in the treatment of depression. A randomized clinical trial. Acta Psychiatr Scand 1984;70:254-260.
138. Larsen JK, Holm P, Hoyer E, et al. Moclobemide and clomipramine in reactive depression. A placebo-controlled randomized clinical trial. Acta Psychiatr Scand 1989;79:530-536.
139. Larsen JK, Gjerris A, Holm P, et al. Moclobemide in depression: A randomized multicentre trial against isocarboxazide and clomipramine emphasizing atypical depression. Acta Psychiatr Scand 1991;84:564-570.
140. Lauerma H. A case of moclobemide-induced hyperorgasmia. Int Clin Psychopharmacol 1995;10:123-124.
141. Laux G, Beckmann H, Classen W, et al. Moclobemide and maprotiline in the treatment of inpatients with major depressive disorder. J Neural Transm 1989;Suppl 28:45-52.
142. Laux CG. Moclobemide in long-term treatment of depression. Psychiatr Prax 1990;17:26-29.
143. Laux G, Volz H-P, Möller H-J. Newer and older monoamine oxidase inhibitors. A comparative profile. CNS Drugs 1995;3:145-158.
144. Lecrubier Y, Guelfi JD. Efficacy of reversible inhibitors of monoamine oxidase A in various forms of depression. Acta Psychiatr Scand 1990;82(Suppl 360):18-23.
145. Lecrubier Y, Pedarriosse A-M, Payan C, et al. Moclobemide vs. clomipramine in nonmelancholic, nonpsychotic major depression. Acta Psychiatr Scand 1995;92:260-265.
146. Lemoine P, Miraboud C. A double-blind comparison of moclobemide and toloxatone in out-patients presenting a major depressive disorder. Psychopharmacology 1992;106:S118-S119.
147. Liebowitz MR, Gorman JM, Fyer AJ, et al. Pharmacotherapy of social phobia: An interim report of a placebo-controlled comparison of phenelzine and atenolol. J Clin Psychiatry 1988;49:252-257.
148. Liebowitz MR, Schneier FR, Campeas R, et al. Phenelzine vs. atenolol in social phobia: A placebo-controlled comparison. Arch Gen Psychiatry 1992;49:290-300.
149. Lingjaerde O, Jorgensen J, Storen R, et al. A double-blind comparison of moclobemide and doxepin in depressed general practice patients. Acta Psychiatr Scand 1995;92:125-131.
150. Livingston MG, Livingston HM. Monoamine oxidase inhibitors. An update of drug interactions. Drug Safety 1996;14:219-227.
151. Loerch B, Graf-Morgenstern M, Hautzinger M, et al. Randomized placebo-controlled trial of moclobemide, cognitive-behavioral therapy and their combination in panic disorder with agarophobia. Br J Psychiatry 1999;174:205-212.
152. Lonnqvist J, Sintonen H, Syvälathi E, et al. Antidepressant efficacy and quality of life in depression: A double-blind study with moclobemide and fluoxetine. Acta Psychiatr Scand 1994;89:363-369.
153. Lonnqvist J, Shivo S, Syvälathi E, et al. Moclobemide and fluoxetine in atypical depression: A doubleblind trial. J Affect Disord 1994;32:169-177.
154. Lonnqvist J, Sihvo S, Syvälathi E, et al. Moclobemide and fluoxetine in the prevention of relapses following acute treatment of depression. Acta Psychiatr Scand 1995;91:189-194.
155. Lotufo-Neto F, Trivedi M, Thase ME, Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology 1999;20:226-247.
156. Macher JP, Miraboud C. A double-blind comparison of moclobemide and amineptine in the treatment of depressed outpatients. Psychopharmacology 1992;106:S116-S117.
157. McFarlane HJ. 6-S and the new generation monoamine oxidase inhibitors, 6-S 1994;49:597-599.
158. McIntyre IM, King CV, Staikos V, et al. A fatality involving moclobemide, sertraline, and pimozide. J Forensic Sci 1997;42:951-953.
159. Mann K, Pamkok J, Leissner J, et al. Effects of moclobemide on sexual performance and nocturnal erections in psychogenic erectile dysfunction. Psychopharmacology 2001;156:86-91.
160. Marley E, Wozniak KM. Clinical and experimental aspects of interactions between amine oxidase inhibitors and amine re-uptake inhibitors. Psychol Med 1983;13:735-749.
161. Mayersohn M, Guentert TW. Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide. Clin Pharmacokinet 1995;29:292-332.
162. Medical Economics Company, Inc. Physicians' Desk Reference 53rd Edn. Medical Economics Company, Inc., Montvale, New Jersey, 1999.
163. Meienberg O, Amsler F. Moclobemide in the prophylactic treatment of migraine. A retrospective analysis of 44 cases. Eur Neurol 1996;36:109-110.
164. Mitchell PB. Drug interactions of clinical significance with selective serotonin reuptake inhibitors. Drug Safety 1997;17:390-406.
165. Moll E, Hetzel W. Moclobemide (RO 11-1163) safety in depressed patients. Acta Psychiatr Scand 1990;82(Suppl 360):69-70.
166. Moll E, Neumann N, Schmidt-Burgk W, et al, Safety and efficacy during long-term treatment with moclobemide. Clin Neuropharmacol 1994;17(Suppl 1):S74-S87.
167. Montgomery SA, Dufour H, Brion S, et al. The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry 1988;152(Suppl 3):69-76.
168. Montejo AL, Llorca G, Izquierdo JA, et al. Incidence of sexual dysfunction associated with antidepressant agents: A prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 2001;62(Suppl 3):10-21.
169. Montgomery SA. Social phobia: diagnosis, severity and implications for treatment. Eur Arch Psychiatry Clin Neurosci 1999;249(Suppl 1):S1-S6.
170. Myronuk LDS, Weiss M, Cotter L. Combined treatment with moclobemide and methylphenidate for comorbid major depression and adult attention-deficit/hyperactive disorder. J Clin Psychopharmacol 1996;16:468-469.
171. Nair NPV, Amin M, Holm P, et al. Moclobemide and nortriptyline in elderly depressed patients. A randomized, multicentre trial against placebo. J Affect Disord 1995;33:1-9.
172. Neal LA, Shapeland W, Fox C. An open trial of moclobemide in the treatment of post-traumatic stress disorder. Int Clin Psychopharmacol 1997;12:231-237.
173. Nelson JC. Augmentation strategies in depression 2000. J Clin Psychiatry 2000;61(Suppl 2):13-19.
174. Neuvonen PJ, Pohjola-Sintonen S, Tacke U, et al. Five fatal cases of serotonin syndrome after moclobemide-citalopram overdoses. Lancet 1993;342:1419.
175. Newborn GM, Fraser AR, Menkes DB, et al. A double-blind trial of moclobemide vs. amitryptiline in the treatment of depressive disorders. Aust NZ J Psychiatry 1990;24:475-479.
176. Newburn G, Edwards R, Thomas H, et al. Moclobemide in the treatment of major depressive disorder (DSM-3) following traumatic brain injury. Brain Injury 1999;8:637-642.
177. Norman TR, Ames D, Burrows CD, et al. A controlled study of a specific MAO-A reversible inhibitor (Ro 11-1163) and amitryptiline in depressive illness. J Affect Disord 1985;8:29-35.
178. Noyes R, Moroz G, Davidson JRT, et al. Moclobemide in social phobia: A controlled dose-response trial. J Cin Psychopharmacol 1997;17:247-254.
179. Nutt D, Montgomery SA. Moclobemide in the treatment of social phobia. Int Clin Psychopharmacol 1996;11(Suppl 3):77-82.
180. O'Cane GM, Gottlieb T. Severe adverse reaction to moclobemide. Lancet 1996;347:1329-1330.
181. Ohberg A, Erkki V, Klaukka T, et al. Antidepressants and suicide mortality. J Affect Disord 1998;50:225-233.
182. Ononye F, Sijuola OA, Chukwuani CM, et al. Open comparative randomised study of moclobemide vs. placebo in major depressive illness (DSM IIIR) in Nigeria. WAJM 2000;19:148-153.
183. O'Reardon JP, Amsterdam JD. Treatment-resistant depression: Progress and limitations. Psychiatr Ann 1998;28:633-640.
184. Ose E, Holm P. Moclobemide and placebo in mild major depression - a double-blind randomised trial. Psychopharmacology 1992;106:S114-S115.
185. Pancheri P, Delle-Chiaie R, Donnini M, et al. Effects of moclobemide on depressive symptoms and cognitive performance in a geriatric population: A controlled comparative study vs. imipramine. Clin Neuropharmacol 1994;17(Suppl 1):S58-S73.
186. Partonen T, Lönnqvist J. Moclobemide and fluoxetine in treatment of seasonal affective disorder. J Affect Disord 1996;41:93-99.
187. Paykel ES. Classification of depressed patients: A cluster analysis derived grouping. Br J Psychiatry 1971;188:275-288.
188. Pélissolo A, Lépine J-P. Psychopharmacological approaches to the treatment of anxiety disorders: A critical review and practical guidelines. In: de Boer JA (ed). Clinical management of anxiety. Marcel Dekker, NY, 1997:249-297.
189. Persad E, Oluboka OJ. The loss of therapeutic effect of antidepressant medication. Can J Psychiatry 1995;40:361-362.
190. Pétursson H. Studies of reversible and selective inhibitors of monoamine oxidase A in dysthymia. Acta Psychiatr Scand 1995;91(Suppl 386):36-39.
191. Phillip M, Kohnen R, Benkert O. A comparison study of moclobemide and doxepin in major depression with special reference to effects on sexual dysfunction. Int Clin Psychopharmacol 1993;7:149-153.
192. Phillip M, Tiller JWG, Baier D, et al. Comparison of moclobemide with selective serotonin reuptake inhibitors (SSRIs) on sexual function in depressed adults. Eur Neuropsychopharmacol 2000;10:305-314.
193. Pohl R, Yeregani V, Balon R, et al. The jitterness syndrome in panic disorder patients treated with antidepressants. J Clin Psychiatry 1988;49:100-104.
194. Power BM, Pinder M, Hackett LP, et al. Fatal serotonin syndrome following a combined overdose of moclobemide, clomipramine and fluoxetine. Anaesth Intens Care 1995;23:499-502.
195. Preskorn SH. Klinische Pharmakologie der selektiven Serotonin-Wiederaufnahmehemmer. Professional Communications, Caddo (USA), 1997.
196. Priest RG, Schmid-Burgk W. Moclobemide in the treatment of depression. Rev Contemp Pharmacother 1994;5:35-43.
197. Quitkin FM, McGrath PJ, Steward JW, et al. Phenelzine and imipramine in mood reactive depressives: Further delineation of the syndrome of atypical depression. Arch Gen Psychiatry 1989;46:787-793.
198. Raybakowski JK. Moclobemide in pregnancy. Pharmacopsychiatry 2001;34:82-83.
199. Ramasubbu R. Switching to moclobemide to reverse fluoxetine-induced sexual dysfunction in patients with depression. J Psychiatry Neurosci 1999;24:45-50.
200. Ramaekers JG, Swijgman HF, O'Hanlon JF. Effects of moclobemide and mianserin on highway driving, psychomotor performance and subjective parameters, relative to placebo. Psychopharmacology 1992;106: S62-S67.
201. Reynaert C, Parent M, Mirel J, Janne P, Haazen L. Moclobemide vs. fluoxetine for a major depressive episode. Psychopharmacology 1995;118:183-187.
202. Rimón R, Jääskeläinen J, Kaartinen P, et al. Moclobemide vs. imipramine in depressed out-patients: A double blind multi-centre study. Int Clin Psychopharmacol 1993;7:141-147.
203. Rodge S, Hilberg T, Teige B. Fatal combined intoxication with new antidepressants. Human cases and experimental study of postmortem moclobemide redistribution. Forens Sci Intern 1999;100:109-116.
204. Roth M, Mountjoy CQ, Amrein R. Moclobemide in elderly patients with cognitive decline and depression. Br J Psychiatry 1996;168:149-157.
205. Ruggieri S, Fabbrini G, Bramante L, et al. An open study with reversible MAO-A inhibitors in complicated Parkinson's disease. Adv Neurol 1996;69:595-598.
206. Saunders PA, Copeland JR, Dewey ME, et al. The prevalence of dementia, depression and neurosis in later life: The Liverpool MRC-ALPHA Study. Int J Epidemiol 1993;22:838-847.
207. Schneier FR, Goetz D, Campeas R, et al. Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry 1998;172:70-77.
208. Schoerlin M-P, Horber FF, Frey FJ, et al. Disposition kinetics of moclobemide, a new MAO-A inhibitor, in subjects with impaired renal function. J Clin Pharmacol 1990;30:272-284.
209. Schoerlin MP, Mayersohn M, Hoevels B, et al. Cimetidine alters disposition kinetics of the monoamine oxidase-A inhibitor moclobemide. Clin Pharmacol Ther 1991;49:32-38.
210. Sieradzan K, Channon S, Ramponi C, et al. The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's disease. J Clin Psychopharmacol 1995;15(Suppl 2):51S-59S.
211. Silver H, Aharon N, Hausfater N, et al. The effect of augmentation with moclobemide on symptoms of schizophrenia. Int Clin Psychopharmacol 1999;14:193-195.
212. Silverstone T, Abou-Saleh MT, Pathak R, et al. A multicentre comparative trial of moclobemide, imipramine and placebo in major depressive disorder. Int Clin Psychopharmacol 1993;9:109-113.
213. Silverstone T. Moclobemide vs. imipramine in bipolar depression: A multicentre double-blind clinical trial. Acta Psychiatr Scand 2001;104:104-109.
214. Simmons F, Metha S. Serotonin syndrome caused by overdose with moclobemide. J Accid Emerg Med 1999;16:293-295.
215. Singer PP, Jones GH. An uncommon fatality due to moclobemide and paroxitine. J Anal Toxicol 1997;21:518-520.
216. Skowron DM, Stimmel GK. Antidepressants and the risk of seizures. Pharmacotherapy 1992;12:18-22.
217. Spigset O, Mjörndal T, Lovheim O. Serotonin syndrome caused by a moclobemide-clomipramine interaction. Br Med J 1993;306:248.
218. Spoov J, Suominen JY, Lahdelma R-L, et al. Do reversed depressive symptoms occur together as a syndrome? J Affect Disord 1993;27:131-134.
219. Stabl M, Bizière W, Schmid-Burgk W, et al. Review of comparative clinical trials. Moclobemide vs. tricyclic antidepressants and vs. placebo in depressive states. J Neural Transm 1989;Suppl 28:77-89.
220. Stabl M, Kasas A, Blajev B, et al. A double-blind comparison of moclobemide and thioridazine vs. moclobemide and placebo in the treatment of refractory, severe depression. J Clin Psychopharmacol 1995;15(Suppl 2):41S-45S.
221. Stack GG, Rogers P, Linter SPK. Monoamine oxidase inhibitors and anaesthesia. A review. Br J Anaesth 1988;60:22-227.
222. Stassen HH, Angst J, Delini-Stula A. Fluoxetine vs. moclobemide: Cross-comparison between the time courses of improvement. Pharmacopsychiatry 1999;32:56-60.
223. Stefanis CN, Alevizos B, Papadimitriou GN. Controlled clinical study of moclobemide, (Ro 11-1163), a new MAO inhibitor, and desimipramine in depressive patients. In: Tipton KF, Dostert P, Strolin-Benedetti M (eds). Monoamine oxidase and disease. Prospects for therapy with reversible inhibitors. London: Academic Press, 1984:377-392.
224. Stefanis CN, Merz-Frei K. Moclobemide (Ro 11-1163) in long-term treatment. Acta Psychiatr Scand 1990;82(Suppl 360):67-68.
225. Steiger A, Holsboer F, Benkert O. Long term studies on the effect of tricyclic antidepressants and selective MAO-A inhibitors on sleep, nocturnal penile tumescence and hormonal secretion in normal controls. In: Koella WP (ed): Sleep. Stuttgart, Verlag, 1988:335-337.
226. Steinberg R, Jost C, Weess HG, et al. Combination of tricyclic antidepressants with moclobemide or tranylcypromine - outcome data in therapy resistant MD. Neuropsychopharmacology 1994;10:35:62.
227. Steinmeyer EM, Vorbach EU, Amoldt KH. Efficacy and safety of moclobemide compared with maprotiline in treatment of major depressive disorder - a double-blind multicenter study with parallel groups. Pharmacopsychiatry 1993;26:246-253.
228. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-713.
229. Sternic N, Kacar A, Filipovic S, et al. The therapeutic effect of moclobemide, a reversible selective monoamine oxidase A inhibitor, in Parkinson's Disease. Clin Neuropharmacol 1998;21:93-96.
230. Stoeckel K, Pfefen JP, Mayersohn M, et al. Absorption and disposition of moclobemide in patients with advanced age or reduced liver or kidney function. Acta Psychiatr Scand 1990;82(Suppl 360):94-97.
231. Swinkels JA, de Jonghe F. Safety of antidepressants. Int Clin Psychopharmacol 1995;9(Suppl 4):19-25.
232. Takats A, Tarczy N, Simo M, et al. Moclobemide/aurorix treatment in Parkinson's disease with depression. New Trends Clin Neuropharmacol 1994;8:260.
233. Tanghe A, Geerts S, van Dorpe J, et al. Double-blind randomized controlled study of the efficacy and tolerability of two reversible monoamine oxidase A inhibitors, pirlindole and moclobemide, in the treatment of depression. Acta Psychiatr Scand 1997;96:134-141.
234. Taylor D, Reveley A, Faivre F. Clozapine-induced hypotension treated with moclobemide and Bovril. Br J Psychiatry 1995;167:409-410.
235. Thase ME, Sullivan LR. Relapse and recurrence of depression. A practical approach for prevention. CNS Drugs 1995;4:261-277.
236. Tiller J, Maguire K, Davies B. A sequential double-blind controlled study of moclobemide and mianserin in elderly depressed patients. Int J Geriatr Psychiatry 1990;5:199-204.
237. Tiller JWG. Post-stroke depression. Psychopharmacology 1992;106:S130-S133.
238. Tiller JWG, Johnson GFS, Burrows GD. Moclobemide for depression: An Australian Practice Study. J Clin Psychopharmacol 1995;15(Suppl 2):31S-34S.
239. Tiller JWG, Bouwer C, Behnke K. Moclobemide for anxiety disorders: A focus on moclobemide for panic disorder. Int Clin Psychopharmacol 1997;12(Suppl 6):S27-S30.
240. Tiller JWG, Bouwer, Behnke K & International Panic Disorder Study Group. Moclobemide and fluoxetine in panic disorder. Eur Arch Psychiatry Clin Neurosci 1999;249(Suppl 1):S7-S10.
241. Timmings P, Lamont D. Intrahepatic cholestasis associated with moclobemide leading to death. Lancet 1996;347:762-763.
242. Trott GE, Friese HJ, Menzel M, et al. Use of moclobemide in children with attention deficit hyperactivity disorder. Psychopharmacology 1992;106:S134-136.
243. Tyrer P, Candy J, Kelly DA. A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety. Psychopharmacologia 1973;32:237-254.
244. Ucha Udabe R, Marquez CA, Traballi CA, et al. Double blind comparison of moclobemide, imipramine and placebo in depressive patients. Acta Psychiatr Scand 1990;82(Suppl 360):54-56.
245. Uzbay IT, Sever B, Celik T, et al. Investigation of the effects of moclobemide in chronic ethanol feeding rats. Pharmacol Res 1995;32:287-292.
246. Vartzopoulos D, Krull F. Dependence on monoamine oxidase inhibitors in high dose. Br J Psychiatry 1991;158:856-857.
247. Vaz-Serra A, Figueira ML, Firmino H, et al. Multicenter double-blind study of moclobemide and maprotiline. Clin Neuropharmacol 1994;17(Suppl 1):S38-S49.
248. Versiani M, Mundim FD, Nardi AE, et al. Tranylcypromine in social phobia. J Clin Psychopharmacol 1988;8:279-283.
249. Versiani M, Oggeru U, Alterwain P, et al. A double blind comparative trial of moclobemide vs. imipramine and placebo in major depressive episodes. Br J Psychiatry 1989;155(Suppl 6):72-77.
250. Versiani M, Nardi AE, Figueira ILV, Stabe M. Tolerability of moclobemide, a new inhibitor of monoamine oxidase A, compared with antidepressants and placebo. Acta Psychiatr Scand 1990;82(Suppl 360):24-28.
251. Versiani M, Nardi AE, Mundim FD, et al. Pharmacotherapy of social Phobia. A controlled study with moclobemide and phenelzine. Br J Psychiatry 1992;161:353-360.
252. Versiani M, Nardi D, Capponi R, et al. Moclobemide compared with imipramine in the treatment of chronic depression (dysthymia DSM-III-R): A double-blind placebo-controlled trial. Clin Neuropharmacol 1992;15(Suppl 1):148b.
253. Versiani M, Amrein R, Stabl M and the International Collaborative Study Group. Moclobemide and imipramine in chronic depression (dysthymia): An international double-blind, placebo-controlled trial. Int Clin Psychopharmacol 1997;12:183-193.
254. Versiani M, Amrein R, Montgomery SA. Social phobia: long-term treatment outcome and prediction of response - a moclobemide study. Int Clin Psychopharmacol 1997;12:239-254.
255. Vida S, Looper K. Precision and comparability of adverse event rates of newer antidepressants. J Clin Psychopharmacol 1999;19:416-426.
256. Walker V, Streiner DL, Novosel S, et al. Health-related quality of life in patients with major depression who are treated with moclobemide. J Clin Psychopharmacol 1995;15(Suppl 2):60S-57S.
257. Wallnöfer A, Guentert TW, Eckernäs SA, et al. Moclobemide and fluvoxamine co-administration: A prospective study in healthy volunteers to investigate the potential development of the "serotonin syndrome." Hum Psychopharmacol 1995;10:25-31.
258. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients. JAMA 1989;262:914-915.
259. Wesnes KA, Simpson PM, Christmas L, et al. The effects of moclobemide on cognition. J Neural Transm 1989;28(Suppl):91-102.
260. Wesnes K, Simpson PM, Jansson B, et al. Moxonidine and cognitive function: Interactions with moclobemide and lorazepam. Eur J Clin Pharmacol 1997;52:351-358.
261. Williams R, Edwards RA, Newburn GM, et al. A double-blind comparison of moclobemide and fluoxetine in the treatment of depressive disorders. Int Clin Psychopharmacol 1993;7:155-158.
262. Young JD, Cohen DJ, Waldo MD, et al. Platelet monoamine oxidase activity in children and adulescents with psychiatric disorders. Schizophren Bull 1980;6:324-333.
263. Zaccara G, Muscas GC, Messofi A. Clinical features, pathogenesis and management of drug-induced seizures. Drug Safety 1990;5:109-151.
264. Zajecka JM. Clinical Issues in long-term treatment with antidepressants. J Clin Psychiatry 2000;61(Suppl 2):20-25.
265. Zimmer R, Gieschke R, Fischbach R, et al. Interaction studies with moclobemide. Acta Psychiatr Scand 1990;82(Suppl 360):84-86.